Review on modeling anti-antibody responses to monoclonal antibodies

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 41, Issue 5, 2014, Pages 523-536

  Gómez Mantilla, José David ^a   Trocóniz, Iñaki F ^a   Parra Guillén, Zinnia ^b   Garrido, María J ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Anti antibodies; Anti drug antibodies (ADA); Immunogenicity; Monoclonal antibodies (mAb); PKPD modeling

Indexed keywords

DRUG ANTIBODY; MONOCLONAL ANTIBODY; ANTIIDIOTYPIC ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; COMPARTMENT MODEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR WEIGHT; NONHUMAN; REVIEW; TREATMENT RESPONSE; BIOLOGICAL MODEL; BIOSYNTHESIS; IMMUNOLOGY;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; HUMANS; MODELS, IMMUNOLOGICAL;

EID: 84910107846     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-014-9367-z     Document Type: Review

References (50)

1. Chames P, Van Regenmortel M, Weiss E, Baty D (2009) Therapeutic antibodies: successes, limitations and hopes for the future. Br J Pharmacol 157:220–233. doi:10.1111/j.1476-5381.2009.00190.x
2. Reichert JM (2013) Antibodies to watch in 2013: mid-year update. MAbs 5:513–517. doi:10.4161/mabs.24990
3. Sethu S, Govindappa K, Alhaidari M et al (2012) Immunogenicity to biologics: mechanisms, prediction and reduction. Arch Immunol Ther Exp (Warsz) 60:331–344. doi:10.1007/s00005-012-0189-7
4. Harding F a, Stickler MM, Razo J, DuBridge RB (2010) The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2:256–265
5. Putnam WS, Prabhu S, Zheng Y et al (2010) Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies. Trends Biotechnol 28:509–516. doi:10.1016/j.tibtech.2010.07.001
6. Bendtzen K (2003) Anti-IFN BAb and NAb antibodies: a minireview. Neurology 61:S6–S10
7. Schwickart M, Mehrzai F, Pearson J et al (2014) Identification and elimination of target-related matrix interference in a neutralizing anti-drug antibody assay. J Immunol Methods 403:52–61. doi:10.1016/j.jim.2013.11.018
8. Van Beers MMC, Bardor M (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins. Biotechnol J 7:1473–1484. doi:10.1002/biot.201200065
9. Singh SK (2010) Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 100:354–387. doi:10.1002/jps.22276
10. Ng CM, Loyet KM, Iyer S et al (2014) Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey. Eur J Pharm Sci 51:51–58. doi:10.1016/j.ejps.2013.08.033
11. Steenholdt C (2013) Use of infliximab and anti-infliximab antibody measurements to evaluate and optimize efficacy and safety of infliximab maintenance therapy in Crohn’ s disease. Dan Med J 60:1–24
12. Shah B, Mayer L (2010) Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease. Expert Rev Clin Immunol 6:607–620. doi:10.1586/eci.10.45.Current
13. Chen X, Hickling T, Kraynov E et al (2013) A mathematical model of the effect of immunogenicity on therapeutic protein pharmacokinetics. AAPS J 15:1141–1154. doi:10.1208/s12248-013-9517-z
14. Perez Ruixo JJ, Ma P, Chow AT (2013) The utility of modeling and simulation approaches to evaluate immunogenicity effect on the therapeutic protein pharmacokinetics. AAPS J 15:172–182. doi:10.1208/s12248-012-9424-8
15. Vande Casteele N, Gils A, Singh S et al (2013) Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 108:962–971. doi:10.1038/ajg.2013.12
16. Pouw MF, Krieckaert CL, Nurmohamed MT et al (2013) Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 60:1–6. doi:10.1136/annrheumdis-2013-204172
17. Stubenrauch K, Wessels U, Birnboeck H et al (2010) Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicit. Clin Ther 32:1597–1609. doi:10.1016/j.clinthera.2010.07.021
18. Sailstad JM, Amaravadi L, Clements-Egan a et al (2014) A white paper-consensus and recommendations of a global harmonization team on assessing the impact of immunogenicity on pharmacokinetic measurements. AAPS J 16:488–498. doi:10.1208/s12248-014-9582-y
19. Ternant D, Ducourau E, Perdriger A et al (2013) Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol 78:1–31. doi:10.1111/bcp.12313
20. Xu ZH, Lee H, Vu T et al (2010) Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity. Int J Clin Pharmacol Ther 48:596–607
21. Zhu Y, Hu C, Lu M et al (2009) Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis. J Clin Pharmacol 49:162–175. doi:10.1177/0091270008329556
22. Ng CM, Stefanich E, Anand BS et al (2006) Pharmacokinetics/pharmacodynamics of nondepleting anti-CD4 monoclonal antibody (TRX1) in healthy human volunteers. Pharm Res 23:95–103. doi:10.1007/s11095-005-8814-3
23. Bauer RJ, Dedrick RL, White ML et al (1999) Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J Pharmacokinet Biopharm 27:397–420. doi:10.1023/A:1020917122093
24. Ng CM, Joshi A, Dedrick RL et al (2005) Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 22:1088–1100. doi:10.1007/s11095-005-5642-4
25. Kakkar T, Sung C, Gibiansky L et al (2011) Population PK and IgE pharmacodynamic analysis of a fully human monoclonal antibody against IL4 receptor. Pharm Res 28:2530–2542. doi:10.1007/s11095-011-0481-y
26. Shah DK, Betts AM (2012) Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human. J Pharmacokinet Pharmacodyn 39:67–86. doi:10.1007/s10928-011-9232-2
27. Bourdage JS, Lee TN, Taylor JM et al (2005) Effect of double antigen bridging immunoassay format on antigen coating concentration dependence and implications for designing immunogenicity assays for monoclonal antibodies. J Pharm Biomed Anal 39:685–690. doi:10.1016/j.jpba.2005.03.037
28. Chirmule N, Jawa V, Meibohm B (2012) Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 14:296–302. doi:10.1208/s12248-012-9340-y
29. Swann PG, Tolnay M, Muthukkumar S et al (2008) Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 20:493–499. doi:10.1016/j.coi.2008.05.013
30. Fasanmade a a, Adedokun OJ, Olson a et al (2010) Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 48:297–308
31. Zhou L, Hoofring S a, Wu Y et al (2013) Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics. AAPS J 15:30–40. doi:10.1208/s12248-012-9408-8
32. Joshi A, Bauer R, Kuebler P et al (2006) An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol 46:10–20. doi:10.1177/0091270005283282
33. Bonate PL, Sung C, Welch K, Richards S (2009) Conditional modeling of antibody titers using a zero-inflated poisson random effects model: application to Fabrazyme. J Pharmacokinet Pharmacodyn 36:443–459. doi:10.1007/s10928-009-9132-x
34. Murphy K, Travers P, Walport M (2008) Janeway’s immunobiology. Garl Sci 7:887. doi:10.1086/596249
35. Savic RM, Jonker DM, Kerbusch T, Karlsson MO (2007) Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn 34:711–726. doi:10.1007/s10928-007-9066-0
36. Friberg LE, Karlsson MO (2003) Mechanistic models for myelosuppression. Invest New Drugs 21:183–194
37. Soto E, Keizer RJ, Trocóniz IF et al (2011) Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies. Invest New Drugs 29:984–995. doi:10.1007/s10637-010-9437-z
38. Reverberi R, Reverberi L (2007) Factors affecting the antigen-antibody reaction. Blood Transfus 5:227–240. doi:10.2450/2007.0047-07
39. Foote J, Eisent HN (1995) Kinetic and affinity limits on antibodies produced during immune responses. Proc Natl Acad Sci USA 92:1254–1256
40. Barderas R, Desmet J, Timmerman P et al (2008) Affinity maturation of antibodies assisted by in silico modeling. Proc Natl Acad Sci USA 105:9029–9034. doi:10.1073/pnas.0801221105
41. Björkelund H, Gedda L, Andersson K (2011) Avoiding false negative results in specificity analysis of protein–protein interactions. J Mol Recognit 24:81–89. doi:10.1002/jmr.1026
42. Shah DK, Betts AM (2013) Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human. MAbs 5:1–9. doi:10.4161/mabs.23684
43. Tabrizi M, Bornstein GG, Suria H (2010) Biodistribution mechanisms of therapeutic monoclonal antibodies in health and disease. AAPS J 12:33–43. doi:10.1208/s12248-009-9157-5
44. Kelley M, Ahene AB, Gorovits B et al (2013) Theoretical considerations and practical approaches to address the effect of anti-drug antibody (ADA) on quantification of biotherapeutics in circulation. AAPS J 15:646–658. doi:10.1208/s12248-013-9468-4
45. Lee JW, Kelley M, King LE et al (2011) Bioanalytical approaches to quantify “total” and “free” therapeutic antibodies and their targets: technical challenges and PK/PD applications over the course of drug development. AAPS J 13:99–110. doi:10.1208/s12248-011-9251-3
46. Rojas JR, Taylor RP, Cunningham MR et al (2005) Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578–585. doi:10.1124/jpet.104.079277.coincident
47. Mager DE, Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507–532
48. Mager DE (2006) Target-mediated drug disposition and dynamics. Biochem Pharmacol 72:1–10. doi:10.1016/j.bcp.2005.12.041
49. Parra-Guillen ZP, Janda A, Alzuguren P et al (2013) Target-mediated disposition model describing the dynamics of IL12 and IFNγ after administration of a mifepristone-inducible adenoviral vector for IL-12 expression in mice. AAPS J 15:183–194. doi:10.1208/s12248-012-9423-9
50. Mager DE, Neuteboom B, Efthymiopoulos C et al (2003) Receptor-mediated pharmacokinetics and pharmacodynamics of interferon-beta1a in monkeys. J Pharmacol Exp Ther 306:262–270. doi:10.1124/jpet.103.049502